Literature DB >> 28213903

Specifics of fetuin-A levels in distinct types of chronic heart failure.

Michael Lichtenauer1, Bernhard Wernly1, Vera Paar1, Ilonka Rohm2, Christian Jung3, Atilla Yilmaz4, Uta C Hoppe1, Paul Christian Schulze2, Daniel Kretzschmar2, Rudin Pistulli2.   

Abstract

INTRODUCTION: Fetuin-A has been described to correlate inversely with vascular calcification both in animal models but also in patients with heart and renal disease. In this current study, we sought to investigate whether fetuin-A might be a useful marker for the discrimination of ischemic (ICM) from dilated cardiomyopathy (DCM).
METHODS: A total of 124 non-consecutive patients were included in this study, 59 patients suffered from ICM and 65 patients from DCM. Serum samples were obtained during out-patient visits and analyzed for fetuin-A by ELISA.
RESULTS: Median fetuin-A concentration in the overall cohort was significantly lower in ICM patients compared to DCM patients (62.2±16.4 μg/mL vs. 129.6±56.6 μg/mL; P<.001). A positive correlation of fetuin-A levels was found with BMI, cholesterol, LDL/HDL ratio and triglycerides and an inverse correlation with age (r=-.36; P<.001). Moreover, patients suffering from (stable) angina pectoris evidenced lower fetuin-A levels compared to non-symptomatic patients (73.1±22.7 μg/mL vs. 83.7±26.2 μg/mL; P=.047)
CONCLUSIONS: Fetuin-A was shown to be a potential discriminator and biomarker for the differential diagnosis between ICM and DCM. Fetuin-A levels might also be helpful in the process of diagnostic decision-making in regards to invasive management or medical therapy.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  zzm321990ELISAzzm321990; biomarker; cardiomyopathy; fetuin-A; heart failure

Mesh:

Substances:

Year:  2017        PMID: 28213903      PMCID: PMC6816921          DOI: 10.1002/jcla.22179

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  33 in total

1.  Serum fetuin-A, cardiovascular risk factors, and six-year follow-up outcome in patients with coronary heart disease.

Authors:  Marcel Roos; Maximilian von Eynatten; Uwe Heemann; Dietrich Rothenbacher; Hermann Brenner; Lutz P Breitling
Journal:  Am J Cardiol       Date:  2010-04-27       Impact factor: 2.778

Review 2.  Clinical epidemiology of heart failure.

Authors:  Arend Mosterd; Arno W Hoes
Journal:  Heart       Date:  2007-09       Impact factor: 5.994

3.  Red blood cell distribution width as useful tool to predict long-term mortality in patients with chronic heart failure.

Authors:  Christian Jung; Buntaro Fujita; Alexander Lauten; Michael Kiehntopf; Friedhelm Küthe; Markus Ferrari; Hans-Reiner Figulla
Journal:  Int J Cardiol       Date:  2011-09-10       Impact factor: 4.164

4.  Intravital microscopy - A novel tool in characterizing congestive heart failure in experimental autoimmune myocarditis.

Authors:  Rudin Pistulli; Felix Quitter; Elise Andreas; Ilonka Rohm; Daniel Kretzschmar; Hans-R Figulla; Atilla Yilmaz; Christian Jung
Journal:  Clin Hemorheol Microcirc       Date:  2015-10-16       Impact factor: 2.375

Review 5.  Fetuin-A: a novel link between obesity and related complications.

Authors:  J F Trepanowski; J Mey; K A Varady
Journal:  Int J Obes (Lond)       Date:  2014-12-03       Impact factor: 5.095

6.  Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study.

Authors:  Gysèle S Bleumink; Anneke M Knetsch; Miriam C J M Sturkenboom; Sabine M J M Straus; Albert Hofman; Jaap W Deckers; Jacqueline C M Witteman; Bruno H Ch Stricker
Journal:  Eur Heart J       Date:  2004-09       Impact factor: 29.983

7.  The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification.

Authors:  Cora Schafer; Alexander Heiss; Anke Schwarz; Ralf Westenfeld; Markus Ketteler; Jurgen Floege; Werner Muller-Esterl; Thorsten Schinke; Willi Jahnen-Dechent
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

8.  Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients.

Authors:  Ralf Koos; Vincent Brandenburg; Andreas Horst Mahnken; Georg Mühlenbruch; Sven Stanzel; Rolf W Günther; Jürgen Floege; Willy Jahnen-Dechent; Malte Kelm; Harald Peter Kühl
Journal:  Eur Heart J       Date:  2009-05-08       Impact factor: 29.983

9.  Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease.

Authors:  David Peter Lorant; Milan Grujicic; Clemens Hoebaus; Johanna-Maria Brix; Florian Hoellerl; Guntram Schernthaner; Renate Koppensteiner; Gerit-Holger Schernthaner
Journal:  Diabetes Care       Date:  2010-10-07       Impact factor: 19.112

10.  Plasma levels of fetuin-A and risk of coronary heart disease in US women: the Nurses' Health Study.

Authors:  Qi Sun; Monik C Jiménez; Mary K Townsend; Eric B Rimm; JoAnn E Manson; Christine M Albert; Kathryn M Rexrode
Journal:  J Am Heart Assoc       Date:  2014-06-24       Impact factor: 5.501

View more
  2 in total

1.  Specifics of fetuin-A levels in distinct types of chronic heart failure.

Authors:  Michael Lichtenauer; Bernhard Wernly; Vera Paar; Ilonka Rohm; Christian Jung; Atilla Yilmaz; Uta C Hoppe; Paul Christian Schulze; Daniel Kretzschmar; Rudin Pistulli
Journal:  J Clin Lab Anal       Date:  2017-02-18       Impact factor: 2.352

2.  Social and therapeutic decline earlier than physical and psychological domains after discharge in heart failure patients: A patient-reported outcome measurements of latent transition analysis.

Authors:  Hong Yang; Jing Tian; Jing Li; Linai Han; Gangfei Han; Jinghua Zhao; Qinghua Han; Yanbo Zhang
Journal:  Front Cardiovasc Med       Date:  2022-09-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.